Biotech Sonus Could Soar on Drug Results
BOSTON -- Sonus Pharmaceuticals (SNUS) is nearing a make-or-break milestone for its experimental cancer drug.
The small Seattle-based biotech firm is preparing to release top-line results from a pivotal phase III study of Tocosol paclitaxel, a reformulation of the broadly used chemotherapy drug paclitaxel, which is known by its brand name Taxol.
Sonus' management has indicated that the phase III data should be ready at the end of September, so we're a month away from what should be a significant stock-moving catalyst.
I called this a make-or-break moment for Sonus -- and I mean it. At its Monday closing price of $3.85, Sonus shares could double if its drug is a success. A failure, of course, will send Sonus shares tumbling. The company has about $1.20 a share in cash.The Sonus story is fairly straightforward: The company has developed a proprietary drug delivery technology using vitamin E that allows chemotherapy drugs to be administered much more easily, with less toxicity and fewer side effects. Superior efficacy is also a possibility. Tocosol paclitaxel, or TocP, can be administered to a patient in 15 minutes, compared to the three-hour infusion time for normal Taxol. TocP also doesn't require patients to be pretreated with steroids either, like Taxol does. Sonus' drug should also be less toxic than ordinary Taxol, most importantly with regard to neuropathy, a side effect affecting a patient's peripheral nerves that can cause tingling, numbness and pain.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV